As iPSC therapies transition from promise to clinical reality, the 6th iPSC Drug Development Summit arrives at a pivotal moment for biopharma leaders advancing next-generation cell therapies. Bringing together senior scientists, CMC experts, and decision-makers, this industry-focused meeting is dedicated exclusively to accelerating iPSC-based drug development from discovery through clinical translation and commercialization.

This year’s agenda is designed to address the most pressing challenges across the iPSC pipeline, with a sharp focus on scalability, manufacturability, and regulatory alignment as therapies move toward late-stage clinical success. Attendees will gain practical insights across two core tracks, covering preclinical development and process development & CMC, including genome editing strategies, donor and cell line selection, functional quality control, and GMP-ready manufacturing approaches.

The summit features 25+ expert speakers from leading organizations actively advancing iPSC therapies across indications such as Parkinson’s disease, diabetes, oncology, and ocular disorders.

Speaker highlights include:

• Yanzheng Liu, Senior Director, Aspen Neuroscience
• Rachel Knopp and Yongting Wang, Astellas Pharma
• William Hendriks, Director of PSC Biology, BlueRock Therapeutics
• Eric Law, Head of CMC Regulatory Affairs, Century Therapeutics
• Alex Ng, Chief Scientific Officer, GC Therapeutics
• Marcella Garita-Hernandez, Head of iPS Core, Harvard Medical School

With contributions from organizations including Astellas Pharma, BlueRock Therapeutics, Aspen Neuroscience, Vertex Pharmaceuticals, and more, the meeting provides a unique opportunity to learn directly from teams generating clinical data and overcoming real-world development bottlenecks.

Designed for professionals actively building iPSC pipelines, the summit offers an end-to-end view of the field, alongside collaborative networking with peers across biopharma, academia, and investment. From optimizing early discovery decisions to ensuring commercial readiness, this is the must-attend forum to benchmark strategies and accelerate the path to clinically successful iPSC therapies.

Find out more here: https://ter.li/japojzin

This meeting is free to attend* for biopharma and academics.